Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US

[1]  E. Bouza,et al.  Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection , 2023, Open forum infectious diseases.

[2]  L. Siegartel,et al.  379. A budget impact analysis of bezlotoxumab for the management of recurrent Clostridioides difficile infection in the United States , 2022, Open Forum Infectious Diseases.

[3]  S. Khanna,et al.  Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection , 2022, Drugs.

[4]  O. Cornely,et al.  A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany , 2021, BMC Health Services Research.

[5]  E. Obi,et al.  Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States , 2021, Infectious Diseases and Therapy.

[6]  K. Garey,et al.  Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  M. Madin-Warburton,et al.  Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI , 2021, BMC Infectious Diseases.

[8]  W. Nelson,et al.  Mortality, healthcare resource utilization, and cost among Medicare beneficiaries with Clostridioides difficile infection with and without sepsis , 2021, Therapeutic advances in infectious disease.

[9]  W. Nelson,et al.  Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis. , 2021, Journal of managed care & specialty pharmacy.

[10]  W. Nelson,et al.  Clinical complications in patients with primary and recurrent Clostridioides difficile infection: A real-world data analysis , 2021, SAGE open medicine.

[11]  Jennifer E. Moore,et al.  Agency for Healthcare Research and Quality , 2020, Definitions.

[12]  W. Nelson,et al.  Healthcare resource utilization and direct medical costs associated with index and recurrent Clostridioides difficile infection: a real-world data analysis , 2020, Journal of medical economics.

[13]  Antibiotic resistance threats in the United States, 2019 , 2019 .

[14]  E. Crouser,et al.  Epidemiology and Costs of Sepsis in the United States—An Analysis Based on Timing of Diagnosis and Severity Level* , 2018, Critical care medicine.

[15]  M. Olsen,et al.  Clostridium difficile infection increases acute and chronic morbidity and mortality , 2018, Infection Control & Hospital Epidemiology.

[16]  A. Guh,et al.  Clostridioides difficile Infection , 2018, Annals of Internal Medicine.

[17]  N. Petrosillo,et al.  Novel Antimicrobials for the Treatment of Clostridium difficile Infection , 2018, Front. Med..

[18]  K. Carroll,et al.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  Dongmu Zhang,et al.  Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  A. Ananthakrishnan,et al.  A Comprehensive Study of Costs Associated With Recurrent Clostridium difficile Infection , 2016, Infection Control & Hospital Epidemiology.

[21]  Joanne Pascale,et al.  Health Insurance Coverage Reporting Accuracy in the Current Population Survey Annual Social and Economic Supplement , 2016 .

[22]  K. Langa,et al.  Racial and Ethnic Differences in End‐of‐Life Medicare Expenditures , 2016, Journal of the American Geriatrics Society.

[23]  Kay See Tan,et al.  Trends in Critical Care Beds and Use Among Population Groups and Medicare and Medicaid Beneficiaries in the United States: 2000–2010 , 2016, Critical care medicine.

[24]  J. Posnett,et al.  A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany , 2016, Infection.

[25]  Lisa G Winston,et al.  Burden of Clostridium difficile Infection in the United States , 2015 .

[26]  Christine Leong,et al.  Treatment Strategies for Recurrent Clostridium difficile Infection. , 2013, The Canadian journal of hospital pharmacy.

[27]  C. Hollenbeak,et al.  Impact of Clostridium difficile colitis following closure of a diverting loop ileostomy: results of a matched cohort study , 2013, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[28]  Derrick W. Crook,et al.  Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  J. Alverdy,et al.  Diverting Loop Ileostomy and Colonic Lavage: An Alternative to Total Abdominal Colectomy for the Treatment of Severe, Complicated Clostridium difficile Associated Disease , 2011, Annals of surgery.

[30]  B. Limbago,et al.  Clostridium difficile in food and domestic animals: a new foodborne pathogen? , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  S. Stringer.  Economic Analysis , 2002, The Laryngoscope.